NanOlogy Sees ‘Encouraging Signs’ for Its Microparticle Drug Delivery in Nonoperable Lung Cancer Patients

Enrollment is complete for the Fort Worth biotech’s Phase 2a trial of its unique tech-based drug delivery with standard-of-care therapy in patients with nonoperable lung cancer.

Fort Worth-based NanOlogy has completed the enrollment of 18 patients in a Phase 2a trial for its proprietary particle drug delivery with standard-of care therapy in nonoperable lung cancer patients.

Lung cancer is the most lethal form of cancer with the highest mortality rate, according to the biotech, which aims to improve the treatment of cancer with its tumor-directed technology. There were an estimated 1.8 million deaths globally and around 2.2 million new cases by the end of 2020 alone, it said, citing GLOBOCAN statistics.

Preliminary results are encouraging, the biotech reports. The tech-based particle delivery of the chemotherapy drug—known as IT LSAM-PTX, or intratumoral large surface area microparticle paclitaxel—is “well tolerated” with signs of tumor and immune response, NanOlogy said in a news release. Final data and clinical study report are expected by Q3 in 2023.

Safety is the primary outcome measure for the trial, NanOlogy said. Other measures include plasma paclitaxel concentration, tumor response, survival, and immune response.

The biotech plans more clinical research in lung cancer to evaluate its LSAM investigational drugs combined with immune checkpoint inhibitors.  Nanology says these ICIs are “rapidly becoming a standard of care” for treating lung cancer and are “often combined with other agents to increase response.”

Nanology’s nanoscale drug delivery tech

The clinical-stage oncology company’s nanoscale drug delivery tech tackles cancer by sending chemoimmunology agents directly to a tumor. 

The biotech was formed in 2015 by Fort Worth-based private investment and development group DFB Pharmaceuticals in cooperation with two other companies — CritiTech and US Biotest. The company is led by representatives from each company.

Toxicity of cancer drugs can limit treatment, DFB Pharmaceuticals and NanOlogy Chairman and CEO Paul Dorman has said, depending on how much a patient’s body can tolerate. The company’s platform aims to keep cancer drugs at a therapeutic level using nanoparticles. Its patented submicron particle technology is an advanced cancer treatment that can release slowly to give drugs more time to work effectively.

To date, NanOlogy says that clinical programs have advanced its tumor-directed large surface area microparticles—or LSAM—in multiple solid tumors including pancreas, lung, bladder, peritoneal, ovarian, prostate, and dermal cancers. The company reports that more than 170 patients have been treated across its clinical trials “with signals of tumor and immune response and no confirmed drug-related serious adverse events.”

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.
View previous emails.

R E A D   N E X T

  • The Cancer Prevention & Research Institute of Texas has provided more than $3.1 billion in funding toward the development of cancer-fighting therapeutics, devices, diagnostics, and tools since 2010. It's now issued a call for startups and early-stage companies to apply for product development research grants for the 2023 fiscal year. “CPRIT’s mission is to invest in the research prowess of Texas institutions while expediting breakthroughs in cancer cures and prevention,” CEO Wayne Roberts said last May.

  • Brett Giroir named to the board of Onconano

    The former Assistant Secretary of Health and Admiral in the U.S. Public Health Service will help advance Onconano's mission to advance the identification and treatment of cancer.

  • After 10 years of working toward a more sustainable future worldwide, EarthX is doubling down on its move into television. The Dallas-based environmental organization is ramping up its EarthxTV streaming service with a new leadership team of TV veterans—with plans to eventually announce traditional and digital 24x7 linear distribution deals.

  • Dallas Innovates and D CEO celebrated 78 honorees and revealed the winners of our third-annual Innovation Awards at an event held at The Perot Museum of Nature and Science. Here's a full list of winners and finalists.

  • Dr. Ahn is working on something very small that may have a profound, lifesaving impact on something hugely dangerous. In collaboration with UTSW Medical Center professor Dr. Ganesh Raj and UTHSC San Antonio's Ratna Vadlamudi, Ahn has created a molecule that can kill an array of cancers, including an aggressive form of breast cancer. The goal of the molecules is to prevent molecular “handshakes” between proteins that can cause out-of-control cell growth that spreads cancer further.